Navigation Links
The most natural drug

In the fight against infection, the human immune system isnt ready for a war.

Vaccines push the immune system to create defenses against illness, but they take time to work. A new process developed by scientists at the Oklahoma Medical Research Foundation (OMRF) and Emory University stands to revolutionize the process.

In an advance online publication in Nature, the researchers describe a method that can identify and clone human antibodies specifically tailored to fight infections. The new technology holds the potential to quickly and effectively create new treatments for influenza and a variety of other communicable diseases.

When an infection invades, the immune system goes to work manufacturing antibodies to fight it. Most of the antibodies created will have no effect, but a very few will bond to the invader and replicate to neutralize the enemy.

The new process develops a smart bomb for the immune system, using fully human monoclonal antibodies specifically designed to fight the infection without doing any harm to the body. The work was led by OMRFs Patrick Wilson, Ph.D., and J. Donald Capra, M.D., and Emorys Rafi Ahmed, Ph.D., and Jens Wrammert, Ph.D.

In the past, it took years of work and great expense to create what are known as monoclonal antibodieslab-produced antibodies derived from a single line of cells. It was kind of the needle in a haystack approach, said OMRFs Wilson, senior author on the paper. The problem is they couldnt pick the cells that made the antibodies against the pathogens that you wanted to fight.

A second method, making hybrid antibodies from mouse B cells (white blood cells that produce infection-fighting antibodies), is faster but more dangerous. If the proteins in the hybrid antibodies werent compatible, the body could reject the antibodies or react with them in unforeseen ways.

The new process doesnt use traditional antibody derivation methods or human-mouse hybrids. Instead, the OMRF and Emory researchers isolated antibody-secreting cells (plasma cells) from people who had received the influenza vaccine, then cloned the antibody genes from these cells.

We can recognize which cells are made and then make antibodies from them directly, Wilson said. Its a rapid and efficient way to make fully human antibodies.

While the research is aimed at combating influenza, it can be used to create treatments for any conditionsuch as anthrax or smallpoxfor which there is already a vaccine. Antibodies might also be produced from the immune responses of people with active or chronic infections. This technology has the potential to serve as therapy for someone who is already infected or provide passive immunity to protect against future infection.

Vaccines can activate the immune system, but they need time to take effect, and many offer less than 100 percent protection and carry risks of side effects, OMRF President Stephen Prescott, M.D., said. With further research and testing, this new method might allow a nurse going into the center of an outbreak to receive a shot to keep her safe from infection. Soldiers in the field could keep a shot of anti-anthrax in their packs in case of a biological attack.

With more research, this new technology could also be key to fighting diseases such as multiple sclerosis and cancer, Prescott said.

Wilson and his clinical collaborator, OMRFs Judith James, M.D., Ph.D., are currently working to make more antibodies from other infectionsincluding hepatitis C, pneumococcal pneumonia, and anthrax. Theyre also seeking a partner to help produce large quantities of the influenza antibodies.

We now have an outstanding opportunity to create antibodies against a host of diseases, James said. This discovery has great clinical potential.


Contact: Adam Cohen
Oklahoma Medical Research Foundation

Related biology technology :

1. FDA Clears First Medical Product Made From Yulex(R) Natural Rubber
2. AGI Dermatics Clinical Data Identifies L-Ergothioneine as Part of Skins Natural Antioxidant System
3. Natural Nutrition Launches International Marketing Campaign for New All Natural Analgesic: BLUE LIGHTNING(TM) Fast Pain Relief
4. Human Pheromone Sciences Enters Into Agreement to Reposition and Promote its Natural Attraction(R) Brand
Post Your Comments:
(Date:6/23/2016)... , June 23, 2016   Boston Biomedical ... novel compounds designed to target cancer stemness pathways, ... been granted Orphan Drug Designation from the U.S. ... of gastric cancer, including gastroesophageal junction (GEJ) cancer. ... designed to inhibit cancer stemness pathways by targeting ...
(Date:6/23/2016)... -- A person commits a crime, and the detective uses ... criminal down. An outbreak of foodborne illness makes ... uses DNA evidence to track down the bacteria that caused ... not. The FDA has increasingly used a complex, cutting-edge technology ... Put as simply as possible, whole genome sequencing is a ...
(Date:6/23/2016)... ... June 23, 2016 , ... Charm Sciences, Inc. ... test has received AOAC Research Institute approval 061601. , “This is another AOAC-RI ... stated Bob Salter, Vice President of Regulatory and Industrial Affairs. “The Peel Plate ...
(Date:6/23/2016)... -- The Biodesign Challenge (BDC), a university competition that asks ... systems and biotechnology, announced its winning teams at the ... York City . The teams, chosen ... MoMA,s Celeste Bartos Theater during the daylong summit. Keynote ... of architecture and design, and Suzanne Lee , ...
Breaking Biology Technology:
(Date:4/19/2016)... UAE, April 20, 2016 The ... as a compact web-based "all-in-one" system solution for all ... fingerprint reader or the door interface with integration authorization ... access control systems. The minimal dimensions of the access ... into the building installations offer considerable freedom of design ...
(Date:4/14/2016)... AVIV, Israel , April 14, 2016 ... Behavioral Authentication and Malware Detection, today announced the appointment ... already assumed the new role. Goldwerger,s leadership ... BioCatch, on the heels of the deployment of its ... addition, BioCatch,s behavioral biometric technology, which discerns unique cognitive ...
(Date:3/31/2016)... , March 31, 2016  Genomics firm Nabsys has ... CEO, Barrett Bready , M.D., who returned to ... the original technical leadership team, including Chief Technology Officer, ... Product Development, Steve Nurnberg and Vice President of Software ... the company. Dr. Bready served as CEO ...
Breaking Biology News(10 mins):